Florajen3

Phase 2Biologic

MMarquette University

Florajen3 is one of 7 biologic programs targeting Colonization. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ColonizationActive, not recruiting

ColonizationPhase 2

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Colonization

#DrugCompanyPhaseTrials

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Approved

1 2

Allogenic FMT

UUniversity Hospital, Ghent

Phase 3

1 3

Bactroban

PPadagis LLC

Preclinical

4 4

Donor FMT

FFondazione Policlinico Universitario Agostino Gemelli IRCCS

Phase 2

2 5

Florajen3

MMarquette University

Phase 2

1 6

Xylitol

JJoseph Zabner

Phase 1

1 7

Pluronic

UUniversity of Virginia

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Colonization1 trial

The Efficacy of Probiotics to Reduce Antepartum Group B Streptococcus Colonization.

Active, not recruiting·MMarquette University·Phase 2·NCT03696953·109 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Florajen3. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Florajen3 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Florajen3. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Marquette University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: MMarquette University

Florajen3

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Colonization1 trial

References

Drug Info

Quick Facts

Related News